Where Europe’s ‘BeNeLuxA’ Joint Pricing Pilot May Have Gone Wrong

 
• By Francesca Bruce
  
Generate a summary of this article
Listen to this article
Beta

A more innovative approach to pricing and reimbursement arrangements is needed in the pilot BeNeLuxA joint pricing negotiations, says Eurordis head Yann Le Cam. The Netherlands and Belgium are expected to re-start the negotiations soon after a “time-out” period.

Business meeting
BeNeLuxA Pilot Pricing Talks To Continue • Source: Shutterstock

Pilot joint pricing negotiations between the Netherlands, Belgium and the US company Vertex over the cystic fibrosis drug Orkambi (lumacaftor/ivacaftor) must steer away from a “business as usual” approach to pricing arrangements if participants wish to succeed in securing access to the drug, according to Yann Le Cam, chief executive officer of Eurordis, the European Organisation for Rare Diseases.

The pilot is part of the BeNeLuxA initiative, so far made up of Belgium, the Netherlands, Luxembourg and Austria, which...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By Saba Afreen

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     
    • By Anabel Costa-Ferreira and Ian Schofield

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography